The fight against the health pandemic continues. We already have vaccines from Pfizer (NYSE:PFE), BioNTech (NASDAQ:BNTX), and Moderna Inc. (NASDAQ:MRNA). Johnson & Johnson’s (NYSE:JNJ) vaccine is reportedly effective, and could be a game-changer with a single shot after US FDA approval.
“From a practical standpoint, it means that the new vaccine could really speed up America’s vaccination campaign — certainly more than another two-dose vaccine would. It also fixes a problem that’s long bedeviled medical treatments that require multiple doses: A lot of patients tend to drop off after the first appointment,” as reported by Vox.com.
Helping, Pfizer and BioNTech, for example, just begun an evaluation of the safety and immunogenicity of a third dose of the Pfizer-BioNTech vaccine to understand the effect of a booster on immunity against CV caused by the circulating and potential newly emerging variants. The study will draw upon participants from the Phase 1 study in the United States who will be offered the opportunity to receive a 30 µg booster of the current vaccine 6 to 12 months after receiving their initial two-dose regimen.
Moderna even just tapped Baxter International to help fill vials and package about 60 to 90 million doses of vaccine, according to Reuters. “Under the pact with Baxter, the fill and finish of Moderna vaccine will take place at the sterile manufacturing facilities located in Indiana.”